Pharmaceutical composition for inhibiting peritoneal dissemination

Abstract

A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof.

1 . A pharmaceutical composition for treating a peritoneal dissemination and/or preventing the peritoneal dissemination, comprising a connective tissue growth factor (CTGF) and/or an active fragment thereof. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein CTGF and/or the active fragment thereof inhibits at least one matter selected from the group consisting of a cancer cell adhering to a peritoneal cavity, a formation of a peritoneal nodule and an activity of a trigger of an immune response. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein CTGF is a recombinant CTGF and/or the active fragment of CTGF is one selected from the group consisting of a C-terminal (CT) domain, a mutant of the CT domain, an active fragment of the recombinant CTGF and a combination thereof. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the peritoneal dissemination is caused by at least one cancer selected from the group consisting of colon cancer, gastric cancer and ovary cancer. 
     
     
         5 . The pharmaceutical composition according to  claim 1  further comprising an effective dosage of CTGF and/or the active fragment thereof. 
     
     
         6 . The pharmaceutical composition according to  claim 1  further comprising a pharmaceutically acceptable carrier. 
     
     
         7 . A pharmaceutical composition for treating a peritoneal carcinoma recurrence and/or preventing the peritoneal carcinoma recurrence, comprising a connective tissue growth factor (CTGF) and/or an active fragment thereof. 
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein the peritoneal carcinoma recurrence is occurred after surgery. 
     
     
         9 . The pharmaceutical composition according to  claim 7  further comprising a pharmaceutical acceptable carrier. 
     
     
         10 . A method for screening a compound for inhibiting a peritoneal dissemination, comprising steps of:
 (a) providing a compound to contact with a cell expressing a connective tissue growth factor (CTGF), wherein CTGF can inhibit the cell adhering to a peritoneal tissue;   (b) measuring a first amount of the expression of CTGF of the cell; and   (c) determining whether the first amount is higher than a reference amount, wherein an increase in the first amount relative to the reference amount is indicative of the compound that can inhibit the peritoneal dissemination.   
     
     
         11 . The method according to  claim 10 , wherein the cell is selected from a peritoneal tissue. 
     
     
         12 . The method according to  claim 10 , wherein the reference amount is determined by the second amount of the expression of CTGF of the cell without being contacted with the compound. 
     
     
         13 . The method according to  claim 10 , wherein the peritoneal dissemination is caused by at least one cancer selected from the group consisting of colon cancer, gastric cancer and ovary cancer. 
     
     
         14 . The method according to  claim 10 , wherein the cell is selected from the group consisting of Caco-2 cell line, HT29 cell line, LoVo cell line and HCT116 cell line. 
     
     
         15 . A method for measuring a possibility of a peritoneal dissemination being occurring to a patient, comprising steps of
 (a) providing a peritoneal tissue from the patient;   (b) measuring the first amount of an expression of a connective tissue growth factor (CTGF) of the peritoneal tissue; and   (c) comparing the first amount with a reference amount, wherein a decrease in the first amount relative to the reference amount is indicative of a possibility of the peritoneal dissemination being occurring to the patient.   
     
     
         16 . The method according to  claim 15 , wherein the reference amount is determined by the second amount of the expression of CTGF of a normal peritoneal tissue. 
     
     
         17 . The method according to  claim 15 , wherein the patient has at least one cancer selected from the group consisting of colon cancer, gastric cancer and ovary cancer. 
     
     
         18 . A method for measuring a possibility of a peritoneal carcinoma recurrence occurring to a patient, comprising steps of
 (a) providing a peritoneal tissue from the patient;   (b) measuring a first amount of an expression of a connective tissue growth factor (CTGF) of the peritoneal tissue; and   (c) comparing the first amount with a reference amount, wherein a decrease in the first amount relative to the reference amount is indicative of a possibility of a peritoneal carcinoma recurrence occurring to the patient.   
     
     
         19 . The method according to  claim 18 , wherein the reference amount is determined by the second amount of the expression of CTGF of a normal peritoneal tissue. 
     
     
         20 . The method according to  claim 18 , wherein the patient has at least one cancer selected from the group consisting of colon cancer, gastric cancer and ovary cancer. 
     
     
         21 . A method for inhibiting a peritoneal dissemination of a patient, comprising a step of providing the patient with a connective tissue growth factor (CTGF) and/or an active fragment thereof. 
     
     
         22 . A method for inhibiting a peritoneal carcinoma recurrence of a patient, comprising a step of: administering the patient with a connective tissue growth factor (CTGF) and/or an active fragment thereof. 
     
     
         23 . The method according to  claim 21 , wherein a patient comprises a mammal. 
     
     
         24 . The method according to  claim 22 , wherein the mammal further comprises a rodent and a human.